Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

By T. Curiel, Shuang Wei, Haidong Dong, Xavier Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. Knutson, B. Daniel, M. Zimmermann and 12 more. Nature Medicine, 2003

1,357 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/3dc11de0e841e3812c313a1f7ff43c8002057e55

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Lieping Chen
2. W. Zou
3. D. Pardoll
4. D. Gabrilovich
5. E. Wherry
6. G. Freeman
7. J. Wolchok
8. D. Munn

Citations in the corpus

• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity (2004, background): “B7-H1-specific antagonist monoclonal antibody enhanced T-cell responses in vitro and inhibited ovarian tumour growth in a xenografted mouse mode”
• Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11 (2019, background): “The major immunosuppressive mechanisms in the tumor microenvironment include high PD-L1 expression (39, 40) and regulatory T-cell infiltration (41).”
• Immunosuppressive strategies that are mediated by tumor cells. (2007, background): “In addition, blockade of PD-1/PD-L1 interactions improved DC-mediated antitumor activity in vivo, suggesting another cellular target of PD-1-mediated negative regulation (91).”
• Inhibitory B7-family molecules in the tumour microenvironment (2008, background): “In the absence of PD-1 or if binding to PD-1 is blocked, B7-H1 can have a stimulatory effect on T-cell immunit”
• Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “Meanwhile, VEGF is also able to facilitate immune tolerance by upregulating PD-L1 expression on the DC surface [205].”
• PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “However, after activation, these human tumor–associated plasmacytoid DCs are capable of producing large amount of type I IFN (154, 155).”